氯沙坦钾对慢性肾小球肾炎患者血清尿酸的影响

被引：16

作者：

李雪

张蓓茹

杨旭

李德天

机构：

[1] 中国医科大学附属盛京医院肾脏内科

来源：

实用药物与临床 | 2015年 / 18卷 / 06期

关键词：

氯沙坦钾; 慢性肾小球肾炎; 尿酸; 24h尿蛋白; 血压;

D O I：

10.14053/j.cnki.ppcr.201506011

中图分类号：

R692.31 [];

学科分类号：

摘要：

目的评价氯沙坦钾、缬沙坦、替米沙坦治疗慢性肾小球肾炎的疗效及对尿酸的影响。方法选择2013年5月至2014年5月于我院住院的148例原发性慢性肾小球肾炎患者。按照治疗方法不同,分为氯沙坦钾组(54例)、缬沙坦组(48例)、替米沙坦组(46例)。观察对比治疗3个月后患者血清尿酸、血压、24 h尿蛋白定量、血清白蛋白及肾功能变化。结果治疗3个月后,氯沙坦钾组患者血清尿酸由(378.18±108.58)降至(325.91±99.04),治疗前后比较差异有统计学意义(P<0.01);治疗前,缬沙坦组、替米沙坦组的血清尿酸分别为(370.75±72.70)、(356.59±91.21),治疗后为(379.08±82.128)、(354.85±59.16),治疗前后比较差异无统计学意义(P>0.05)。氯沙坦钾组治疗后24 h尿蛋白定量、血压、血清白蛋白及肾功能和缬沙坦组及替米沙坦组相似,差异无统计学意义(P>0.05)。结论氯沙坦钾亚除具有降低尿蛋白及降压作用外,还具有良好的降尿酸作用。

引用

页码：669 / 672

页数：4

共 10 条

[1]

Hyperuricemia and chronic kidney disease: an enigma yet to be solved [J].

Dousdampanis, Periklis ;

Trigka, Konstantina ;

Musso, Carlos G. ;

Fourtounas, Costas .

RENAL FAILURE, 2014, 36 (09) :1351-1359

[2]

A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothiazide in patients with hypertension.[J].Toshihiro Hamada;Masanari Kuwabara;Arisa Watanabe;Einosuke Mizuta;Akira Ohtahara;Hiroki Omodani;Masashi Watanabe;Hiroki Nakamura;Yutaka Hirota;Satoshi Miyazaki;Masahiko Kato;Kazuhide Ogino;Hiroki Kosaka;Ninomiya Haruaki;Shin-ichi Taniguchi;Kazuhiro Yamamoto;Hiroshi Kotake;Ichiro Hisatome.Clinical and Experimental Hypertension.2013, 4

[3]

Metabolic syndrome, diabetes, and hyperuricemia [J].

Li, Changgui ;

Hsieh, Ming-Chia ;

Chang, Shun-Jen .

CURRENT OPINION IN RHEUMATOLOGY, 2013, 25 (02) :210-216

[4]

Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008 [J].

Zhu, Yanyan ;

Pandya, Bhavik J. ;

Choi, Hyon K. .

AMERICAN JOURNAL OF MEDICINE, 2012, 125 (07) :679-+

[5]

Uric Acid; Heart Failure Survival; and the Impact of Xanthine Oxidase Inhibition.[J].ArashHarzand;LeonardoTamariz;Joshua M.Hare.Congestive Heart Failure.2012, 3

[6]

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials [J].

Smink, Paul A. ;

Bakker, Stephan J. L. ;

Laverman, Gozewijn D. ;

Berl, Tomas ;

Cooper, Mark E. ;

de Zeeuw, Dick ;

Lambers Heerspink, Hiddo J. .

JOURNAL OF HYPERTENSION, 2012, 30 (05) :1022-1028

[7]

Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort.[J].Shao-Yuan Chuang;Jiunn-Horng Chen;Wen-Ting Yeh;Chih-Cheng Wu;Wen-Harn Pan.International Journal of Cardiology.2011, 3

[8]

Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.[J].Kwang Kon Koh;Michael J. Quon;Seung Hwan Han;Yonghee Lee;Soo Jin Kim;Yesl Koh;Eak Kyun Shin.International Journal of Cardiology.2008, 1

[9]

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial [J].